{"id":"lokelma-5-gm-powder-for-oral-suspension","safety":{"commonSideEffects":[{"rate":"approximately 10-15%","effect":"Constipation"},{"rate":"approximately 5-10%","effect":"Nausea"},{"rate":"approximately 5%","effect":"Abdominal discomfort"},{"rate":"approximately 5%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL216657","moleculeType":"Small molecule","molecularWeight":"1203.39"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lokelma is a non-absorbed, selective potassium binder that works in the distal colon by exchanging sodium and hydrogen ions for potassium ions, thereby reducing serum potassium levels. It is designed to treat hyperkalemia by removing potassium from the body through the feces without systemic absorption, making it suitable for chronic management of elevated potassium levels.","oneSentence":"Lokelma (sodium zirconium cyclosilicate) is a potassium binder that traps potassium in the gastrointestinal tract and increases fecal potassium excretion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:52:51.836Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hyperkalemia (elevated serum potassium levels)"}]},"trialDetails":[{"nctId":"NCT05535920","phase":"PHASE4","title":"A Prospective, Randomized, Open-Label, Cross-Over Study of Lokelma to Control Interdialytic Hyperkalemia","status":"COMPLETED","sponsor":"NephroNet, Inc.","startDate":"2022-04-14","conditions":"Hyperkalemia","enrollment":88},{"nctId":"NCT04063930","phase":"PHASE4","title":"The Effect of Sodium Zirconium Cyclosilicate on Albuminuria in Patients With Type 2 Diabetes and Hyperkalemia","status":"UNKNOWN","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2019-10","conditions":"Type 2 Diabetes Mellitus With Kidney Complications","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"LOKELMA 5 GM Powder for Oral Suspension","genericName":"LOKELMA 5 GM Powder for Oral Suspension","companyName":"Steno Diabetes Center Copenhagen","companyId":"steno-diabetes-center-copenhagen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lokelma (sodium zirconium cyclosilicate) is a potassium binder that traps potassium in the gastrointestinal tract and increases fecal potassium excretion. Used for Hyperkalemia (elevated serum potassium levels).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}